Professor Gus Gazzard Latest News
The National Institute for Health Research (NIHR) Dissemination Centre has published an NIHR Signal on Professor Gazzard's research.
You can view the Signal here: A laser eye procedure can be effective and safe if used early as a treatment for glaucoma.The prestigious medical journal The Lancet published results from a pioneering research study, funded by the National Institute of Health Research (NIHR) and led by Professor Gus Gazzard. Read the full article published in The Lancet here.
Gus Gazzard reflects on his pioneering glaucoma research in the following video:
The Moorfields Glaucoma Service Director Professor Gus Gazzard discusses a non-invasive glaucoma treatment that could reduce the need for eye drops. Includes a 7 minute video interview with Professor Gazzard by Optometry Today.
"A laser could end the inconvenience of eye drops for glaucoma" - Article in the Daily Mail 26.08.19
Guy Staniforth, 62, a project engineer from Greenwich in South-East London, tells ADRIAN MONTI about having the operation by Professor Gazzard.
The prestigious medical journal The Lancet published results from a pioneering research study, funded by the National Institute of Health Research (NIHR) and led by Professor Gus Gazzard, consultant ophthalmologist and Glaucoma Service Director at Moorfields Eye Hospital.
The results of the three-year trial showed that using laser-based treatment on newly diagnosed cases of glaucoma was more successful and more cost-effective than the current method of using intraocular pressure lowering eye drops. There was also less need for treatment to be escalated and there was a reduced need for both glaucoma surgery and cataract extractions compared with patients who received the eye drops.
The results could potentially improve the way glaucoma is treated across the world and, if the treatment proves to be as effective with patients who have had the condition for some time, could save the NHS hundreds of millions of pounds a year.
The National Institute for Health Research (NIHR) Dissemination Centre has published an NIHR Signal on Mr. Gazzard’s research.
PARIS — The HORIZON trial at 3 years demonstrated that the Hydrus Schlemm’s canal stent added sustained IOP lowering to that achieved by cataract surgery alone, Gus Gazzard, MD, MBBChir, FRCOphth, said at the European Society of Cataract and Refractive Surgeons meeting.
“That intraocular pressure was stable, significantly better than control after 3 years,” Gazzard said.
SLT is an effective intervention for newly-diagnosed patients – and now we can prove it. Article about the research conducted by Professor Gazzard.
In March 2019, The Lancet published results of a three-year trial led by Gus, showing that a laser-based treatment on newly diagnosed cases of glaucoma is more successful and cost-effective than standard treatments. Speaking of his promotion and clinical trials,
Gus said: “I am honoured to have been appointed to a UCL Professorship and I look forward to further developing the clinical trials and excellent postgraduate clinical education that we have established here at the UCL Institute of Ophthalmology. The clinical trials that I work on across the globe are a testament to the great team that I’ve been able to build at the Institute of Ophthalmology and Moorfields Eye Hospital, and a tribute to all of their hard work – the energy they bring to answer questions of real clinical importance to patients with blinding diseases.”
Lasers should become the principal method in the UK for treating patients with the debilitating eye condition glaucoma. That is the stark conclusion of a three-year study published recently.
The Moorfields Eye Charity Flipbook magazine has a feature articles on Professor Gazzard's innovative research.
Professor Gus Gazzard is the author of this definitive review of the data on the main treatment for angle closure glaucoma.
Gus has been awarded the prestigious, competitively awarded “NHS National Bronze Merit Award”.
These awards recognise NHS consultants who perform 'over and above' the standard expected of their role.
NICE (National Institute for Health and Care Excellence) have released a report on Trabecular stent bypass microsurgery for open-angle glaucoma
- European School for Advanced Studies in Ophthalmology
- Optometry Today | Taking stock of glaucoma implants
- Royal Academy of Ophthamologists 'focus' article: Minimally Invasive Glaucoma Surgery (MIGS)
- EGS ACG SIG meeting (PDF)
- Interview with one of Professor Gazzard's patients in the Mail Online
- UK Clinical Research Network paper on the LiGHT SLT Trial Research
- GoodDoctor review
- Moorfields Eye Charity feature